Apple’s blood oxygen measurement trick on the Apple Watch has weathered a patent challenge without being ruled an outright infringement. A US tribunal determined that the method does not directly violate patents held by Masimo, effectively sidestepping immediate legal consequences for Apple while preserving the feature’s availability.
The ruling centers on nuanced technical differences between Apple’s approach and those protected by Masimo’s patents. While Apple avoids direct infringement, the decision doesn’t preclude future disputes or broader implications for competing oxygen measurement technologies in wearables or medical devices.
What This Means for Users
For everyday users, the outcome is straightforward: no changes are expected to the feature’s functionality or accessibility. However, small businesses integrating similar tech—especially those relying on third-party hardware or software—may still encounter supply chain or pricing challenges unrelated to this ruling.
- Apple’s method bypasses patented steps without violating core protections.
- No immediate impact on consumer access or performance.
- Future legal risks remain for competitors, but Apple is cleared for now.
A Look Under the Hood
The tribunal’s analysis focused on how Apple’s algorithm processes light signals from the Watch’s sensors. Unlike Masimo’s patented techniques, which rely on specific calibration or signal processing, Apple’s implementation avoids those exact steps while achieving comparable results. This distinction—subtle but critical—allows Apple to continue using the feature without triggering patent enforcement.
What’s Next?
The ruling doesn’t resolve all uncertainties. While Apple is in the clear for now, other companies developing oxygen measurement tech may need to reassess their designs or licensing strategies. Supply and pricing could still fluctuate based on market dynamics, but legal barriers have been removed for at least one major player.
